BioSpace News Archive

Delta 4, a biotech company using its proven digital drug discovery platform to identify new indications for approved drugs, today announced recent results achieved in two drug discovery and development programs. In its lead program,

CryoTreq adds to BVI’s rapidly expanding vitreoretinal portfolio including Vitreq® single-use instruments and Arcad® surgical fluids

TORONTO, June 3, 2020 /PRNewswire/ - Akumin Inc. announced its financial results for the quarter ended March 31, 2020 and an amendment to its existing credit agreement effective June 2, 2020.

InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announced the pricing of an underwritten public offering of 22,222,200 units at a price to the public of $0.45 per unit.

Global Blood Therapeutics, Inc. announced that on June 1, 2020, the compensation committee of GBT’s board of directors granted seven new employees restricted stock units for an aggregate of 34,000 shares of the company’s common stock.

Histogen Inc. (NASDAQ: HSTO), a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it will be featured as a presenting company at BIO Digital 2020, being held virtually June 8-12, 2020. In addition to completion of its merger with Conatus Pharmaceuticals in May 2020, enrollment is currently underway in Histogen’s Phase 1b/2a clinical trial of its lead product candi

Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company’s partner in China has been approved by the Chinese National Medical Products Administration (NMPA) to initiate clinical trials for IV oliceridine, Trevena’s lead investigational asset for the management of moderate-to-severe acute

Blueprint Medicines Corporation announced that, effective on June 1, 2020, the Compensation Committee of Blueprint Medicines’ Board of Directors granted non-qualified stock options to purchase an aggregate of 49,493 shares of its common stock and an aggregate of 24,745 restricted stock units to four new employees under Blueprint Medicines’ 2020 Inducement Plan.

InfuTronix Solutions LLC, a company that develops safer, simple to use, advanced ambulatory infusion solutions, announced being awarded an agreement with Premier Inc., a leading supply chain solutions and total cost management organization that serves nearly 4,000 hospitals nationwide.

Incyte announced that it will present at the following investor conferences during the month of June